Plasma cell-free RNA PD-L1 expression and survival with immune checkpoint inhibitor-based treatment in advanced non-small-cell lung cancer

被引：0
|
作者：
Walker, Paul R. [1 ]
Jayananda, Sriraksha [1 ]
Pasli, Melisa [1 ]
Muzaffar, Mahvish [1 ]
机构：
[1] East Carolina Univ, Brody Sch Med, Greenville, NC 27858 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21090
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer
    Lisberg, Aaron
    Garon, Edward B.
    JAMA ONCOLOGY, 2016, 2 (05) : 571 - 572
  • [22] The immune checkpoint, HVEM may contribute to immune escape in non small cell lung cancer lacking PD-L1 expression
    Ren, Shengxiang
    Tian, Qinrui
    Amar, Nadav
    Yu, Hui
    Rivard, Christopher J.
    Caldwell, Charles
    Ng, Terry L.
    Tu, Megan
    Liu, Yiwei
    Gao, Dexiang
    Ellison, Kim
    Suda, Kenichi
    Rozeboom, Leslie
    Rivalland, Gareth
    Mitchell, Paul
    Zhou, Caicun
    Hirsch, Fred R.
    LUNG CANCER, 2018, 125 : 115 - 120
  • [23] PD-L1 expression is associated with advanced non-small cell lung cancer
    Chen, Zhiquan
    Mei, Jiandong
    Liu, Lunxu
    Wang, Guochen
    Li, Zuosheng
    Hou, Jingpu
    Zhang, Qiuyang
    You, Zongbing
    Zhang, Liu
    ONCOLOGY LETTERS, 2016, 12 (02) : 921 - 927
  • [24] Association of PD-L1 expression with clinicopathologic features and overall survival in patients with non-small-cell lung cancer
    Zhou, Yan
    Liu, Xianxun
    Hu, Zhangguo
    Zhong, Runbo
    Han, Baohui
    Zhong, Hua
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (02): : 1954 - 1961
  • [25] Neutrophil to lymphocyte ratio, PD-L1 expression, and survival in patients with advanced non-small cell lung cancer receiving first-line immune checkpoint inhibitor therapy
    Li, Mingjia
    Zhao, Songzhu
    Spakowicz, Daniel
    Burkart, Jarred Thomas
    Patel, Sandip H.
    Husain, Marium
    He, Kai
    Bertino, Erin Marie
    Shields, Peter G.
    Wei, Lai
    Presley, Carolyn J.
    Otterson, Gregory Alan
    Owen, Dwight Hall
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [26] Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
    Yin, Jianqiong
    Wu, Yuanjun
    Yang, Xue
    Gan, Lu
    Xue, Jianxin
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] Plasma Cell-Free RNA PD-L1 Expression and Clinical Outcomes With Immunotherapy
    Jayananda, S.
    Muzaffar, M.
    Namireddy, P.
    Sharma, N.
    Walker, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (02): : E9 - E9
  • [28] ACTIVITY AND SAFETY OF CAMRELIZUMAB, AN ANTI-PD-1 IMMUNE CHECKPOINT INHIBITOR, FOR PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER
    Sun, Guo Gui
    Jia, Jing Hao
    Gao, Peng
    Yao, Xue Min
    Chen, Ming Da
    Yao, Wei Nan
    Sun, Lu
    Wang, Wei
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A267 - A268
  • [29] PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
    Larsen, Trine Vilsboll
    Hussmann, Dianna
    Niesen, Anders Lade
    CANCER COMMUNICATIONS, 2019, 39
  • [30] Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Santoro, Ilka
    Babiker, Hani
    Avancha, Kiran
    Gutierres, Barbara
    Barreto, Carmelia
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S169 - S170
12345